Presumptive antibiotic therapy for hospitalized children with sepsis and meningitis: Cost-effective analysis and antibiotic restriction guidelines

Pediatric Annals

Volumn 25, Issue 11, 1996, Pages 631-638

  Jacobs, Richard F ^a,b   Stimson, J Mel ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL MENINGITIS; CHILD; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DRUG UTILIZATION; ECONOMICS; HOSPITALIZATION; HUMAN; SEPSIS;

ANTI-BACTERIAL AGENTS; CHILD; COST-BENEFIT ANALYSIS; DRUG UTILIZATION; HOSPITALIZATION; HUMANS; MENINGITIS, BACTERIAL; PHYSICIAN'S PRACTICE PATTERNS; SEPSIS;

EID: 0030277308     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-19961101-09     Document Type: Article

References (23)

1. Adams WG, Deaver KA, Cochi SL, et al Decline of childhood Haemophilus influenzae type b (HIB) disease in the Hib vaccine era. JAMA 1993,269:221-226.
2. Schutze GE, Kaplan SL, Jacobs RF Resistant pneumococcus a worldwide problem. Infection 1994;22.233-237.
3. Tan TQ, Schutze GE, Mason EO Jr, et ai. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad spectrum cephalosporins. Antimicrob Agents Chemother 1994;38:918-923.
4. McCracken GH, Nelson JD, Kaplan SL, et al Consensus report antimicrobial therapy for bacterial meningitis in infants and children. Pediatr Infect Dis J 1987;6:501-505.
5. Friedland IR, McCracken OH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994;331:377-382
6. Woods CR, Givner LB. Drug-resistant meningococcal infections Sem Pediatr Infect Dis 1996;7 204-221
7. Committee on Infectious Diseases, American Academy of Pediatrics. Staphylococcal food poisoning. In Red Boole. Elk Grove Village, III. American Academy of Pediatrics; 1994:428-439
8. Jacobs RF, Sowell MK, Moss MM, et al Septic shock in children: bacterial etiologies and temporal relationships Pediatr Infect Dis J. 1990;9:196-200
9. Darville T, Giroir B, Jacobs R The systemic inflammatory response syndrome (SIRS): immunology and potential immunotherapy Infection 1993;21:279-290
10. Baumgartner ET, Augustine RA, Steele RW. Bacterial meningitis in older neonates Am J Dis Child. 1983;137:1052-1054.
11. Shulman ST, Avoub EM. Severe staphylococcal sepsis m adolescents Pediatrics 1976,58:59-66
12. Hieber P, Nelson AJ, McCracken GH Jr Acute disseminated staphylococcal disease in childhood Am J Dis Child 1977,131:181-185
13. Darville T, Jacobs RF, Trang JM, et al Pharmacokinetic evidence supporting an 8-hour administration interval for cefotaxime in infants and children Clinical Drug Investigation 1995,9:206-211.
14. Jacobs RF, Kaplan SL, Schutze GE, et al Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections Antimicrob Agents Chemother 1996;40 895-898
15. Goldwater PN Effect of cefotaxime OT ceftriaxone treatment on nasopharyngeal Haemophilus influenzae type b colonization in children Antimicrob Agents Chemother 1995;39.2150-2152
16. Schwartz B, Al-Tobaiqi A, Al-Ruwais A, et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitis. Lancet 1988,1 1239-1242.
17. Jacobs RF, Darville T, Parks JA, et al Safety profile and efficacy of cefotaxime for the treatment of hospitalized children. Clin Infect Dis 1992;14 56-65
18. Destache CJ Clinical and economic benefits of a clinical pharmacokinetic service 1987 versus 1992 data Medical Interface 1994,7:84-90
19. Shulkin DJ Enhancing the role of physicians in the cost-effective use of pharmaceuticals Hospital Formulary 1994,29:262-273.
20. Centers for Disease Control and Prevention Recommendations for preventing the spread of vancomycin resistance MMWR Morb Mortal Wkly Rep. September 22, 1995.44(RR-12),1-13
21. Schentag JJ, Ballow CH, Fritz AL. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory Diagn Microbiol Infect Dis 1993;16 255-204.
22. Orsini MJ, Funk PA, Thorn DB An ADR surveillance program; increasing quality, number of incidence reports Formulary 1995;30.454-461
23. May JR Adverse drug reactions and interactions. In: DiPiro JT, Talbert RL, Hayes PE, et al, eds Pharmacotherapy A Pathophysiologic Approach 2nd ed. New York, NY Elsevier, 1992 71-83.